ImmunityBio(IBRX) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 ImmunityBio Reports Third-Quarter 2024 Financial Results CULVER CITY, Calif.—Nov. 12, 2024—ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the thirdquarter ended September 30, 2024. ® • ANKTIVA received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. • ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government insurance programs (VA, DoD, Medicare). Immu ...